BRISTOL-MYERS SQUIBB COMPANY Proceeds from Issuance of Commercial Paper
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from Issuance of Commercial Paper of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommercialPaper · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for the quarter ending 2025-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for the quarter ending 2025-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for the quarter ending 2025-06-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for fiscal 2024 was $2.99B.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for fiscal 2023 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from issuance of commercial paper for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Commercial Paper 3 month | Proceeds from Issuance of Commercial Paper 3 month as first filed | Proceeds from Issuance of Commercial Paper 6 month | Proceeds from Issuance of Commercial Paper 9 month | Proceeds from Issuance of Commercial Paper 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $0.00 10-Q · filed 2025-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $2.99B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $2.99B 10-Q · filed 2025-10-30 | $2.99B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $2.99B 10-Q · filed 2025-07-31 | $2.99B derived: sum of 3 quarters · filed 2026-02-11 | $2.99B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $2.99B 10-Q · filed 2025-04-24 | $3.00B 10-Q · filed 2024-07-26 | $2.99B derived: sum of 2 quarters · filed 2026-02-11 | $2.99B derived: sum of 3 quarters · filed 2026-02-11 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-07-26 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |